Dr Brodersen received her PhD from the University of Washington in 2009 and is a board certified High Complexity Laboratory Director (American Board of Bioanalysis) with a subspecialty in hematology. She is an expert in the application of flow cytometry for the diagnosis and treatment monitoring of patients with myeloid neoplasms. Dr Brodersen was the first to identify and characterize the poor prognostic immunophenotype, RAM among pediatric leukemia patients that is associated with the CBFA2T3-GLIS2 fusion transcript. She has monitored thousands of AML patients (adult and pediatric) for MRD by flow cytometry with Hematologics unique difference from normal approach. In addition, she leads translational research, including computational biology efforts, at Hematologics. She is a participant of the Children’s Oncology Group Myeloid Disease Committee, a member of the European LeukemiaNet International MDS flow cytometry working group, and a member of the American Society of Hematology. Dr Brodersen is passionate about leading strong clinical and research teams at Hematologics that have the ability to make discoveries and innovate in the clinical laboratory and pursue true translational research that will improve patient cure rates.